Cerenis is developing HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients, and drugs that increase HDL in patients with low HDL. Cerenis is well-positioned to become the leader in the HDL therapeutic market, with a broad portfolio of programs being developed.
Therapies focused on increasing HDL (good cholesterol) represent the next frontier in the treatment of cardiovascular disease. Clinical evidence has demonstrated that HDL therapy can rapidly regress atherosclerotic plaque and elevating HDL can reduce cardiovascular morbidity and mortality.
Cerenis is developing CER-001 which has the potential to be the first-to-market and best-in-class recombinant HDL (CER-001).
CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport.
CER-001 is being developed to rapidly regress atherosclerotic plaque in high-risk patients. This product is based on the multiple innovations of Cerenis in the science of HDL that allowed the company to identify and develop a recombinant HDL particle of high purity and efficiency.
Market capitalization (23-May-2017)
Closing share price (23-May-2017)